DEF: Natera, Inc. Announces 2025 Annual Meeting of Stockholders and Proxy Statement

Natera, Inc. has scheduled its 2025 Annual Meeting of Stockholders for June 12, 2025, to be held virtually, and has released its proxy statement outlining key proposals for stockholder consideration.

Summary

• Natera, Inc. will hold its 2025 Annual Meeting of Stockholders on June 12, 2025, at 11:30 a.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of April 15, 2025, are entitled to vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent accounting firm, an advisory vote on executive compensation, and an amendment to the 2015 Equity Incentive Plan.
• The board of directors recommends voting for all proposals.
• The company encourages electronic delivery of proxy materials to reduce environmental impact, noting a potential reduction of 42.7 tons of wood, 272 million BTUs of energy, and 192,000 million pounds of greenhouse gas emissions if all stockholders adopted electronic delivery.
• In 2024, Natera achieved \$1,696.9 million in total revenues, a 57% growth over 2023, and processed approximately 3 million tests, a 23% increase over 2023.
• The company's oncology tests grew by 55% in 2024, reaching approximately 528,200 tests.
• Natera launched a new cell-free DNA Fetal RhD noninvasive prenatal test and a donor quantity score for the Prospera Heart transplant test.
• The company expanded Medicare and commercial coverage for Signatera and Prospera products.
• Natera has over 250 peer-reviewed publications, with over 100 in oncology alone, and presented over 300 cumulative posters in oncology since 2017.
• The company acquired reproductive health assets from Invitae Corp. relating to NIPT and carrier screening.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Natera, highlighting strong revenue growth, increased test processing volumes, and expanded market access. While acknowledging risks, the overall tone is optimistic and confident in the company's future prospects.

Positives

• Natera achieved significant revenue growth in 2024, with total revenues reaching \$1,696.9 million, a 57% increase over the previous year.
• The company experienced substantial growth in oncology testing, with a 55% increase in 2024.
• Natera expanded access to care by securing Medicare and commercial coverage for key products like Signatera and Prospera.
• The company continues to innovate, launching new products and features in women's health, oncology, and organ health.
• Natera has a strong foundation of clinical evidence, supported by over 250 peer-reviewed publications.
• The company is committed to sustainability, encouraging electronic delivery of proxy materials to reduce environmental impact.

Risks

• The proxy statement contains forward-looking statements that are subject to known and unknown risks and uncertainties.
• The company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time.
• The company's performance and results in fiscal 2024 are not necessarily indicative of its performance and results in any future period.

Future Outlook

The company's forward-looking statements include statements regarding market opportunity, reimbursement coverage, product costs, financial performance, strategies, goals, and general business and market conditions, all of which are subject to risks and uncertainties.

Management Comments

• Thank you for your ongoing support of Natera, said Steve Chapman, Chief Executive Officer and President.

Industry Context

Natera competes in the diagnostics industry, specifically in the areas of women's health, oncology, and organ health. The company's performance is influenced by factors such as market adoption of genetic testing, reimbursement policies, and competition from other diagnostics companies.

Comparison to Industry Standards

• The document mentions a comparison of Natera's additional share proposal to those of comparable companies in its Global Industry Classification Standard industry group with a market capitalization between \$1 billion and \$40 billion.
• Natera's total potential equity dilution of 15.7% as of March 31, 2025 is positioned well below the median of 21.01% dilution for this group, at the 21st percentile of such requests.
• Natera's share request, which represents 2.65% of its common shares outstanding, is positioned well below the median of 4.25%, and equates to the 18th percentile of such requests.

Related Party Transactions

• Natera has a collaboration and commercialization agreement with MyOme, Inc., in which Matthew Rabinowitz, Natera's executive chairman, is the chairman of the board and founder, and Jonathan Sheena, a Natera director, is a stockholder and board member.
• Natera received warrants to purchase shares of MyOme's common stock and series B preferred stock as part of the collaboration agreement.
• Natera is a beneficial holder of approximately 16.5% of the outstanding shares of MyOme on a fully diluted basis.

Stakeholder Impact

• Stockholders will have the opportunity to vote on key proposals that will shape the company's future direction.
• Patients will benefit from the company's continued innovation and expanded access to genetic testing services.
• Employees will be incentivized to achieve the company's goals through equity-based compensation programs.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 12, 2025.
• The company will continue to execute its strategic initiatives and pursue growth opportunities in women's health, oncology, and organ health.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Equity Incentive Plan, Natera, Genetics, Testing, Oncology, Womens Health, Organ Health